HOOK News and Press, HOOKIPA Pharma Inc. From 05/11/23

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) HB-700 for KRAS-muta...

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Pha...

2023-04-26 15:17:26 ET Shares of immunotherapy company Hookipa Pharma ( NASDAQ: HOOK ) rose for the fourth consecutive session after announcing that it is scheduled to present an overview of its ongoing Phase 1/2 trial for prostate cancer drug HB-300 at an upcoming medical event. ...

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1...

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings...

2023-04-18 17:23:51 ET Summary Hookipa Pharma’s platform has two technologies that are based on arenaviruses that stimulate the immune system to be used to combat infectious diseases or cancer. The replication defective modified arenavirus termed VaxWave, is designed to saf...

NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company...

2023-03-15 12:47:02 ET HOOKIPA Pharma Inc. (HOOK) Q4 2022 Results Conference Call March 15, 2023 08:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Office...

2023-03-14 10:55:10 ET Major earning expected before the bell on Wednesday include: Bayerische Motoren Werke Aktiengesellschaft ( OTCPK:BMWYY ) Calumet Specialty Products Partners ( CLMT ) Kandi Technologies Group ( KNDI ) KNOT Offshore Partners ( KNOP ) ...

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Commi...